8-K
filed April 30, 2026, 7:59 PM ET
ticker LLY
CIK 0000059478
earnings
confidence high
sentiment positive
materiality 0.85
Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo
ELI LILLY & Co
2026-Q1 EPS reported
$8.26
revenue$19,799,000,000
- Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.
- FY2026 revenue guidance raised to $82B-$85B; non-GAAP EPS guidance $35.50-$37.00.
- U.S. FDA approved Foundayo (orforglipron) for obesity—first GLP-1 pill without food/water restrictions.
- Acquired Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.
- Pipeline progress: positive Phase 3 for Foundayo in T2D, Jaypirca combo in CLL, and retatrutide in T2D.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ELI LILLY & Co reported FY 2026 results: revenue 82.0 billion to 85.0 billion, EPS 35.50 to 37.00. Guidance raised.
- Period
- FY 2026
- Revenue
- 82.0 billion to 85.0 billion
- EPS
- 35.50 to 37.00
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ELI LILLY & Co reported Q1 2026 results: revenue 19,799, net income 7,396, EPS 8.26.
- Period
- Q1 2026
- Revenue
- 19,799
- Net income
- 7,396
- EPS
- 8.26
- Result
- reported results
Exact text from the filing
Revenue $ 19,799 $ 12,729 56% Net income – Reported 7,396 2,759 168% Earnings per share – Reported 8.26 3.06 170%
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.